<p>2025 年 5 月 21 日- 下午 2:52</p>
<p><em>Navidea Biopharmaceuticals, Inc. 延長實施反向股票拆分的截止日期</em></p>
<p>俄亥俄州哥倫布市 --（商業新聞）--Navidea Biopharmaceuticals, Inc.（OTC: NAVB）（“Navidea” 或 “公司”）是一家專注於開發精準免疫診斷劑和免疫治療藥物的生物製藥公司，今天宣佈延長其實施反向股票拆分的授權，比例高達 1 股對 50,000 股。</p>
<p>公司最初在 2024 年 7 月 8 日舉行的特別會議上獲得股東批准，修訂其公司章程以授權反向股票拆分，比例高達 1 股對 50,000 股。該授權最初定於 2025 年 7 月 8 日到期，現在已延長兩年至 2027 年 7 月 8 日。該延長獲得了公司董事會的批准，並通過大多數股東的書面行動確認。</p>
<p><em>執行反向股票拆分的決定，包括時機和具體比例，仍由 Navidea 的董事會自行決定。</em></p>
<p><em>“考慮反向股票拆分的理由是多方面的，” Navidea 首席財務官 Craig A. Dais 表示。“隨着我們繼續評估戰略合作伙伴關係和其他融資機會，以推進我們的藥物開發目標，簡化公司的資本結構至關重要。此外，減少我們普通股的記錄持有者數量是保持在美國證券交易委員會（SEC）閾值以下的關鍵步驟，否則將需要持續的公開報告，這會產生顯著成本。如果實施，反向股票拆分將有助於實現這一目標。”</em></p>
<p>關於 Navidea</p>
<p>Navidea Biopharmaceuticals, Inc.（OTC: NAVB）是一家專注於開發精準免疫診斷劑和免疫治療藥物的生物製藥公司。Navidea 正在基於其 Manocept 平台開發多種精準靶向產品，以通過識別疾病的部位和途徑來增強患者護理，並實現更好的診斷準確性、臨牀決策和靶向治療。Navidea 的 Manocept 平台基於能夠特異性靶向在活化巨噬細胞上表達的 CD206 甘露糖受體的能力。Manocept 平台作為 Tc99m tilmanocept 的分子基礎，這是 Navidea 基於該平台開發和商業化的首個產品。Navidea 的戰略是通過推出新產品和推進公司的產品管道，通過全球合作和商業化努力實現卓越的增長和股東回報。有關更多信息，請訪問 www.navidea.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條的定義的前瞻性聲明。我們在很大程度上基於當前的預期和關於影響我們業務財務狀況的未來事件和財務趨勢的預測來制定這些前瞻性聲明。前瞻性聲明包括我們對待決訴訟和其他事項的預期。這些前瞻性聲明受到多種風險、不確定性和假設的影響，包括但不限於：我們經營虧損的歷史和未來盈利能力的不確定性；任何待決訴訟的最終結果；我們成功完成藥物候選者的研究和進一步開發的能力；獲得藥物候選者的監管批准的時間、成本和不確定性；我們成功商業化藥物候選者的能力；對特許權使用費和補助收入的依賴；我們實施增長戰略的能力；我們業務的預期趨勢；我們有限的產品線和分銷渠道；技術進步和新競爭產品的開發；我們保持有效的財務報告內部控制的能力；當前冠狀病毒大流行的影響；以及我們最近的 10-K 表格年報和其他 SEC 文件中詳細列出的其他風險因素。我們敦促您仔細審查和考慮我們在 SEC 文件中找到的披露，這些文件可在 http://www.sec.gov 或 http://ir.navidea.com 獲取。</p>
<p>投資者被敦促考慮包含 “將”、“可能”、“能夠”、“應該”、“計劃”、“繼續”、“設計”、“目標”、“預測”、“未來”、“相信”、“打算”、“期望”、“預期”、“估計”、“項目” 等詞語的聲明，以及這些詞語的否定形式或其他類似詞語，作為不確定的前瞻性聲明。</p>
<p>您被警告不要對任何前瞻性聲明過度依賴，這些聲明可能會被證明是錯誤的。我們沒有義務公開更新或修訂任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，在本報告日期之後。鑑於這些風險和不確定性，本報告中討論的前瞻性事件和情況可能不會發生，實際結果可能與前瞻性聲明中預期或暗示的結果有重大差異。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA1MjA0MjE5NjRyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA1MjA0MjE5NjRyMQ"/></p>
<p>查看商業新聞網站上的源版本：https://www.businesswire.com/news/home/20250520421964/en/</p>
<p><strong>投資者關係聯繫人</strong></p>
<p>Navidea Biopharmaceuticals, Inc.</p>
<p>首席財務官 Craig A. Dais</p>
<p>cdais@navidea.com</p>
<p>(614)-822-2322</p>
<p>來源：Navidea Biopharmaceuticals, Inc.</p>

Navidea生物制藥

NAVBQ

<p>Navidea 生物製藥公司已延長其實施最多 1 股換 50,000 股的反向股票拆分的授權，直到 2027 年 7 月 8 日。此決定經過董事會和股東的批准，旨在簡化公司的資本結構，並減少登記持有者的數量，以避免顯著的公共報告成本。拆分的具體時間和比例將由董事會決定。Navidea 專注於開發精準免疫診斷劑和免疫治療藥物</p>

<p>05/21/2025 - 02:52 PM</p>
<div class="lb-trans"><p>2025 年 5 月 21 日- 下午 2:52</p>
</div><p><em>Navidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split</em></p>
<div class="lb-trans"><p><em>Navidea Biopharmaceuticals, Inc. 延長實施反向股票拆分的截止日期</em></p>
</div><p>COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares.</p>
<div class="lb-trans"><p>俄亥俄州哥倫布市 --（商業新聞）--Navidea Biopharmaceuticals, Inc.（OTC: NAVB）（“Navidea” 或 “公司”）是一家專注於開發精準免疫診斷劑和免疫治療藥物的生物製藥公司，今天宣佈延長其實施反向股票拆分的授權，比例高達 1 股對 50,000 股。</p>
</div><p>The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was initially set to expire on July 8, 2025, has now been extended by two years to July 8, 2027. The extension was approved by the Company’s Board of Directors and confirmed through written action by a majority of its shareholders.</p>
<div class="lb-trans"><p>公司最初在 2024 年 7 月 8 日舉行的特別會議上獲得股東批准，修訂其公司章程以授權反向股票拆分，比例高達 1 股對 50,000 股。該授權最初定於 2025 年 7 月 8 日到期，現在已延長兩年至 2027 年 7 月 8 日。該延長獲得了公司董事會的批准，並通過大多數股東的書面行動確認。</p>
</div><p><em>The decision to execute a reverse stock split, including the timing and specific ratio, remains at the discretion of Navidea’s Board of Directors.</em></p>
<div class="lb-trans"><p><em>執行反向股票拆分的決定，包括時機和具體比例，仍由 Navidea 的董事會自行決定。</em></p>
</div><p><em>“The rationale behind considering a reverse stock split is multifaceted,” said Craig A. Dais, Chief Financial Officer of Navidea. “As we continue to evaluate strategic partnerships and other funding opportunities to advance our pharmaceutical development objectives, it is essential to simplify the Company’s capitalization table. Additionally, reducing the number of record holders of our common stock is a key step toward staying below the SEC threshold that would otherwise require ongoing public reporting, which entails significant costs. If implemented, the reverse stock split would help achieve this objective.”</em></p>
<div class="lb-trans"><p><em>“考慮反向股票拆分的理由是多方面的，” Navidea 首席財務官 Craig A. Dais 表示。“隨着我們繼續評估戰略合作伙伴關係和其他融資機會，以推進我們的藥物開發目標，簡化公司的資本結構至關重要。此外，減少我們普通股的記錄持有者數量是保持在美國證券交易委員會（SEC）閾值以下的關鍵步驟，否則將需要持續的公開報告，這會產生顯著成本。如果實施，反向股票拆分將有助於實現這一目標。”</em></p>
</div><p>About Navidea</p>
<div class="lb-trans"><p>關於 Navidea</p>
</div><p>Navidea Biopharmaceuticals, Inc. (OTC: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, visit www.navidea.com.</p>
<div class="lb-trans"><p>Navidea Biopharmaceuticals, Inc.（OTC: NAVB）是一家專注於開發精準免疫診斷劑和免疫治療藥物的生物製藥公司。Navidea 正在基於其 Manocept 平台開發多種精準靶向產品，以通過識別疾病的部位和途徑來增強患者護理，並實現更好的診斷準確性、臨牀決策和靶向治療。Navidea 的 Manocept 平台基於能夠特異性靶向在活化巨噬細胞上表達的 CD206 甘露糖受體的能力。Manocept 平台作為 Tc99m tilmanocept 的分子基礎，這是 Navidea 基於該平台開發和商業化的首個產品。Navidea 的戰略是通過推出新產品和推進公司的產品管道，通過全球合作和商業化努力實現卓越的增長和股東回報。有關更多信息，請訪問 www.navidea.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條的定義的前瞻性聲明。我們在很大程度上基於當前的預期和關於影響我們業務財務狀況的未來事件和財務趨勢的預測來制定這些前瞻性聲明。前瞻性聲明包括我們對待決訴訟和其他事項的預期。這些前瞻性聲明受到多種風險、不確定性和假設的影響，包括但不限於：我們經營虧損的歷史和未來盈利能力的不確定性；任何待決訴訟的最終結果；我們成功完成藥物候選者的研究和進一步開發的能力；獲得藥物候選者的監管批准的時間、成本和不確定性；我們成功商業化藥物候選者的能力；對特許權使用費和補助收入的依賴；我們實施增長戰略的能力；我們業務的預期趨勢；我們有限的產品線和分銷渠道；技術進步和新競爭產品的開發；我們保持有效的財務報告內部控制的能力；當前冠狀病毒大流行的影響；以及我們最近的 10-K 表格年報和其他 SEC 文件中詳細列出的其他風險因素。我們敦促您仔細審查和考慮我們在 SEC 文件中找到的披露，這些文件可在 http://www.sec.gov 或 http://ir.navidea.com 獲取。</p>
</div><p>Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.</p>
<div class="lb-trans"><p>投資者被敦促考慮包含 “將”、“可能”、“能夠”、“應該”、“計劃”、“繼續”、“設計”、“目標”、“預測”、“未來”、“相信”、“打算”、“期望”、“預期”、“估計”、“項目” 等詞語的聲明，以及這些詞語的否定形式或其他類似詞語，作為不確定的前瞻性聲明。</p>
</div><p>You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward- looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.</p>
<div class="lb-trans"><p>您被警告不要對任何前瞻性聲明過度依賴，這些聲明可能會被證明是錯誤的。我們沒有義務公開更新或修訂任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，在本報告日期之後。鑑於這些風險和不確定性，本報告中討論的前瞻性事件和情況可能不會發生，實際結果可能與前瞻性聲明中預期或暗示的結果有重大差異。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA1MjA0MjE5NjRyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250520421964r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20250520421964/en/</p>
<div class="lb-trans"><p>查看商業新聞網站上的源版本：https://www.businesswire.com/news/home/20250520421964/en/</p>
</div><p><strong>Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>投資者關係聯繫人</strong></p>
</div><p>Navidea Biopharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Navidea Biopharmaceuticals, Inc.</p>
</div><p>Craig A. Dais, Chief Financial Officer</p>
<div class="lb-trans"><p>首席財務官 Craig A. Dais</p>
</div><p>cdais@navidea.com</p>
<div class="lb-trans"><p>cdais@navidea.com</p>
</div><p>(614)-822-2322</p>
<div class="lb-trans"><p>(614)-822-2322</p>
</div><p>Source: Navidea Biopharmaceuticals, Inc.</p>
<div class="lb-trans"><p>來源：Navidea Biopharmaceuticals, Inc.</p>
</div>

Navidea 生物製藥公司宣佈延長實施反向股票分割的授權 | NAVB 股票新聞